Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $114.2 million.

  • Krystal Biotech's Total Liabilities rose 436.33% to $114.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $114.2 million, marking a year-over-year increase of 436.33%. This contributed to the annual value of $114.2 million for FY2025, which is 436.33% up from last year.
  • Per Krystal Biotech's latest filing, its Total Liabilities stood at $114.2 million for Q4 2025, which was up 436.33% from $102.2 million recorded in Q3 2025.
  • Krystal Biotech's Total Liabilities' 5-year high stood at $114.2 million during Q4 2025, with a 5-year trough of $12.4 million in Q1 2021.
  • Its 5-year average for Total Liabilities is $59.3 million, with a median of $42.6 million in 2021.
  • In the last 5 years, Krystal Biotech's Total Liabilities surged by 45248.26% in 2022 and then plummeted by 3811.33% in 2023.
  • Krystal Biotech's Total Liabilities (Quarter) stood at $32.7 million in 2021, then rose by 10.7% to $36.2 million in 2022, then rose by 9.65% to $39.7 million in 2023, then soared by 175.62% to $109.5 million in 2024, then increased by 4.36% to $114.2 million in 2025.
  • Its Total Liabilities was $114.2 million in Q4 2025, compared to $102.2 million in Q3 2025 and $97.7 million in Q2 2025.